TOT Biopharm inaugurates new production facility in China
TOT Biopharm Company has inaugurated a new 50,000m² factory complex in eastern China's Suzhou Industrial Park, Suzhou.
The new complex, which is part of $100m complex, is a specialized branch for research, development, production and marketing of anti-cancer drugs globally.
The complex includes an oral anti-cancer drug plant with separate production facilities for both cytotoxics and non-cytotoxics, an injected anti-cancer drug plant and a GMP bio pilot plant with a capacity of 500L cell culture/ purification/ filling.
TOT Biopharm's new factory complex is also expected to develop the bio-pharmaceutical sector set forth in China's 12th Five-Year Development Planning for Strategic Emerging Industries.
The company's core products include Liposomal technology-based specialty drugs, biologics and innovative drugs.
TOT Biopharm is also planning to commence the second-stage construction to expand its production scale for cancer treatments.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
This report is a crucial resource for industry executives and anyone looking to access key information about "Shire Plc" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report. Buy online from $250